JP2022187460A - Drug treatment management system, drug treatment management method and program - Google Patents

Abstract

To provide a drug treatment management system, method and program capable of assisting a doctor who makes a drug administration plan.SOLUTION: In a drug treatment management system comprising a plurality of doctor terminals used by doctors and a server 20 connected to the plurality of doctor terminals, the doctor terminal comprises an output unit that accepts input of drug dosage data for a patient and data on the serum zinc concentration of the patient, and outputs a recommended value calculated by the server. The server 20 comprises a storage unit 25 that stores the drug dosage and the serum zinc concentration data as time-series data, and a dose calculation unit 26 that obtains a recommended drug dose based on the time-series data.SELECTED DRAWING: Figure 3

Description

TECHNICAL FIELD The present invention relates to a technique for monitoring the therapeutic effect of a drug and assisting in the optimization of treatment by drug administration.

Therapeutic drug monitoring (TDM) is monitoring for performing dosage design suitable for individual patients and performing appropriate drug therapy. While monitoring factors related to therapeutic effects and side effects, individualized dosage regimens are set for each patient. For example, the blood concentration of the drug is measured, and the administration plan is determined based on the analysis results and clinical findings.

Japanese Patent Application Laid-Open No. 2004-555

Since therapeutic drug monitoring establishes a dosage plan based on therapeutic effects and side effects, it is possible to provide detailed treatment for each patient, but the experience and knowledge of individual doctors who formulate dosage plans vary. Even physicians have not encountered every case, so they cannot always come up with the optimal dosing regimen.

In addition, depending on the drug, it is necessary to obtain data that serve as a guideline for the state of the target disease by analyzing a subject's biological sample or the like at the start of administration or at the time of dose change. For example, the dose of zinc acetate, a therapeutic agent for hypozincemia, should be adjusted according to the serum zinc concentration and the patient's condition. ing. When using this zinc acetate formulation, it is extremely important to select an appropriate dosage or to determine whether to increase or decrease the dosage according to the patient's condition in order to ensure patient safety and obtain therapeutic effects. be.

SUMMARY OF THE INVENTION In view of the above background, an object of the present invention is to provide a drug treatment management system that supports a doctor in planning a drug administration plan.

A drug therapy management system of the present invention is a system for managing drug therapy for a patient with hypozincemia, and includes an input unit that receives inputs of drug dosage data for the patient and serum zinc concentration data for the patient. a storage unit for storing data on the drug dose and the serum zinc concentration as time-series data; and a dose calculation unit for calculating a recommended drug dose based on the time-series data stored in the storage unit. and an output unit for outputting the recommended value.

In this way, by outputting a recommended drug dosage based on the drug dosage for the patient and the time-series data of the patient's serum zinc concentration, the doctor can refer to it when formulating a drug administration plan, Can contribute to dosing regimens.

In the drug treatment management system of the present invention, the dosage calculation unit calculates the zinc absorption sensitivity of the patient based on the patient's time-series data, and calculates a recommended drug dosage in consideration of the zinc absorption sensitivity. you may ask. By calculating the zinc absorption sensitivity of each individual patient, which indicates how much zinc is absorbed from the drug taken in this way, it is possible to more appropriately determine the amount of drug recommended to improve symptoms.

In the drug treatment management system of the present invention, the dosage calculation unit may obtain a recommended drug dosage in consideration of the administration period of the drug. The situation is different when the drug is just started and when the drug is being administered for a long time. According to the configuration of the present invention, the recommended value can be obtained more appropriately by taking into account the administration period of the drug.

The drug treatment management system of the present invention comprises a serum zinc concentration prediction unit that calculates predicted changes in the future serum zinc concentration according to the drug dosage based on the time-series data stored in the storage unit, The output unit may output data on the predicted transition of the serum zinc concentration. With this configuration, the doctor can determine the drug dosage while observing future changes in the serum zinc concentration according to the drug dosage when the drug dosage is changed, for example.

In the drug therapy management system of the present invention, the output unit may output a message prompting measurement of serum copper concentration when the input serum zinc concentration is higher than a predetermined threshold. Further, in the drug treatment management system of the present invention, the output unit prompts the measurement of the serum copper concentration when the predicted value of the serum zinc concentration indicated by the calculated predicted transition of the serum zinc concentration is higher than a predetermined threshold. A message may be output. Here, as the value used for determining whether to prompt the measurement of the serum copper concentration, the maximum predicted value of the serum zinc concentration, the trough value, or the like can be used. When serum zinc levels are high, zinc can interfere with copper absorption, resulting in the side effects of copper deficiency. ADVANTAGE OF THE INVENTION According to the structure of this invention, the side effect of copper deficiency can be detected early, and a dosage regimen can be revised if necessary.

The pharmaceutical treatment management system of the present invention includes a number of terminals having the input unit, and a network connected to the terminals, and the drug dosage data and the serum zinc concentration data input from the terminals. and the server analyzes the relationship between drug dosage and serum zinc concentration transition based on the time-series data of the drug dosage and the serum zinc concentration of a large number of patients. An analysis unit may be provided. Based on the drug dosage data and serum zinc concentration data collected from a large number of terminals in this manner, the relationship between the two can be analyzed with high accuracy.

In the drug treatment management system of the present invention, the input unit receives input of patient attribute data or underlying disease data, and the server associates the patient attribute data or underlying disease data with the drug for the patient. The dosage data and the serum zinc concentration data of the patient are stored, and the analysis unit analyzes the patient's attribute data or underlying disease data and the relationship between the drug dosage and changes in the serum zinc concentration. good. Note that the patient attribute data includes, for example, age, sex, and weight.

According to the configuration of the present invention, by considering patient attribute data and underlying disease data, it is possible to more accurately analyze the relationship between drug dosage and changes in serum zinc concentration. The analysis unit may group the data according to patient attributes or underlying diseases, and analyze the relationship between drug dosage and changes in serum zinc concentration. In addition, the analysis unit may determine the relationship between drug dosage, attribute data (age, gender, weight, etc.), and underlying disease data by regression analysis using explanatory variables and changes in serum zinc concentration as objective variables. .

In the drug treatment management system of the present invention, the input unit receives input of data on the type of drug administered to the patient, and the server associates the data on the type of drug administered to the patient with the drug for the patient. The data on the dosage and the data on the serum zinc concentration of the patient may be stored, and the analysis unit may analyze the relationship between the drug type data, the dosage of the drug, and the transition of the serum zinc concentration. Here, the type of drug includes dosage form, active ingredient, component composition (differences in ingredients including additives), product name, and the like. Differences in dosage forms, active ingredients, composition (differences in ingredients such as additives, etc.) may affect responsiveness. The relationship between changes in serum zinc concentration can be analyzed with high accuracy.

In the drug treatment management system of the present invention, the input unit receives input of data of other drugs that the patient is taking, and the server associates the data of the other drugs that the patient is taking with the relevant data. The drug dosage data for the patient and the serum zinc concentration data for the patient may be stored, and the analysis unit may analyze the relationship between the data for other drugs, the drug dosage, and changes in the serum zinc concentration. . Drug responsiveness may be affected by co-administration with other drugs, so data on other drugs taken by patients should be used to accurately assess the relationship between drug dosage and changes in serum zinc concentration. good analysis.

The pharmaceutical treatment management system of the present invention comprises a wearable terminal that measures biological data of a patient and transmits the measured biological data together with the patient's identifier to the server, and the server receives the biological data transmitted from the wearable terminal. It may be stored with the patient's identifier. Here, the biological data of the patient are, for example, blood pressure, heart rate, sleep time, oxygen saturation, and the like. By collecting and storing the patient's biometric data in this way, it is possible to grasp the physical condition of the patient who is taking medicine, and use it as a basis for making a decision when making a medication plan.

A drug therapy management system of the present invention is a system for managing drug therapy for a patient, comprising: an input unit for receiving input of data on a drug administered to the patient and data on the serum elemental concentration of the patient; and the serum elemental concentration data as time-series data; a dosage calculation unit for obtaining a recommended drug dosage based on the time-series data stored in the storage unit; and an output unit for outputting the recommended value.

A drug therapy management method of the present invention is a method of managing drug therapy for a patient with hypozincemia by a drug therapy management system, wherein the drug therapy management system stores drug dosage data for the patient and the patient's serum a step of receiving an input of zinc concentration data; a step of storing the drug dosage and the serum zinc concentration data as time-series data in a storage unit by the drug treatment management system; determining a recommended drug dosage based on series data; and outputting the recommended drug dosage by the drug therapy management system.

A program of the present invention is a program for managing drug therapy for hypozincemia patients by a drug therapy management system, wherein a computer stores drug dosage data for the patient and serum zinc concentration data for the patient. , obtaining a recommended drug dosage based on the time-series data of the drug dosage and the serum zinc concentration, and outputting the recommended dosage.

A program according to another aspect of the present invention is a program for managing drug therapy for a hypozincemia patient by a drug therapy management system, wherein a computer stores drug dosage data for the patient and the patient's serum a step of receiving an input of zinc concentration data, a step of obtaining data on predicted changes in the future serum zinc concentration according to the drug dosage based on the drug dosage and the time-series data of the serum zinc concentration, and a step of outputting data on the predicted transition of the serum zinc concentration. In addition, in the step of outputting the data of the transition of the serum zinc concentration, a plurality of drug dosage candidates and the transition of the serum zinc concentration corresponding to each candidate may be displayed. In this case, the display format may display multiple drug dose candidates and changes in serum zinc concentration corresponding to each candidate on a graph. The maximum value and trough value may be displayed in a tabular form or an itemized form, or may be displayed in a graphic display form such as a heat map.

A pharmaceutical treatment management system according to another aspect of the present invention is a system for managing pharmaceutical treatment for hypozincemia patients, comprising: A determination unit for determining to which class the serum zinc concentration belongs to among classes of a plurality of concentration regions, and an output unit for displaying the class and information corresponding to the class. By displaying the class of serum zinc concentration together with the information corresponding to the class in this way, the patient can easily understand what the data on the serum zinc concentration means.

In the drug therapy management system of the present invention, the information corresponding to the class of the concentration range equal to or higher than the specific value may include a message prompting measurement of the serum copper concentration.

Another aspect of the present invention is a drug therapy management method for managing drug therapy for a hypozincemia patient by means of a drug therapy management system, wherein the drug therapy management system inputs data on the patient's serum zinc concentration. a step of receiving, the pharmaceutical treatment management system determining to which class the input patient serum zinc concentration belongs to among a plurality of concentration region classes; displaying a class and displaying information corresponding to said class.

A program according to another aspect of the present invention is a program for managing drug therapy for a patient with hypozincemia, comprising: determining to which class the serum zinc concentration of the concentration region belongs to, and displaying the class and displaying information corresponding to the class.

According to the present invention, by outputting a recommended dose of a drug based on the time-series data of the dose of the drug and the serum elemental concentration, the doctor can refer to it when planning the administration of the drug, thereby ensuring appropriate administration. Can contribute to planning.

BRIEF DESCRIPTION OF THE DRAWINGS It is a figure which shows the structure of the drug treatment management system of 1st Embodiment. It is a figure which shows the structure of the doctor terminal of 1st Embodiment. It is a figure which shows the structure of the server of 1st Embodiment. 4 is a flow chart showing a dose calculation process of the drug treatment management system of the first embodiment; FIG. 10 is a diagram showing an example of a table showing the relationship between zinc absorption sensitivity and change value; It is a figure which shows the structure of the server of 2nd Embodiment. FIG. 11 is a flow chart showing calculation processing of predictive transition of serum zinc concentration in the drug treatment management system of the second embodiment; FIG. FIG. 10 is a diagram showing a display example of predicted transition of serum zinc concentration in the drug treatment management system of the second embodiment; It is a figure which shows the structure of the drug treatment management system of 3rd Embodiment. It is a figure which shows the structure of the drug treatment management system of 4th Embodiment. FIG. 14 is a diagram showing an example of data stored in a storage unit in the fourth embodiment; FIG. It is a figure which shows the example of the result display screen displayed on an output part in 4th Embodiment. It is a figure which shows the example of the log|history display screen displayed on an output part in 4th Embodiment.

DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, drug treatment management systems according to embodiments of the present invention will be described with reference to the drawings. In the embodiments, a system for supporting the administration schedule of drugs to be administered to hypozincemia patients will be described as an example. Therefore, it can be applied to drug treatments other than hypozincemia.

(First embodiment)
FIG. 1 is a diagram showing the configuration of a drug treatment management system 1. As shown in FIG. The drug treatment management system 1 includes a plurality of doctor terminals 10 used by doctors, and a server 20 connected to the plurality of doctor terminals 10 . The doctor terminal 10 has a function of receiving input of patient data and outputting a recommended drug dosage for the patient. The server 20 has a function of acquiring patient data input at the doctor terminal 10 , calculating a recommended drug value for the patient, and transmitting the recommended value data to the doctor terminal 10 .

Here, we describe the background to drug therapy management systems that recommend drug dosages for hypozincemia. Two types of zinc acetate tablets (Nobelzin (registered trademark) tablets 25 mg, Nobelzin tablets 50 mg) marketed by the applicant are provided as drugs used for the treatment of hypozincemia. In addition to these tablets, the applicant also launched zinc acetate granules (5% Nobelzin granules) in 2021. These preparations are supposed to be used by adjusting the dosage appropriately within the range up to the maximum dosage according to the serum zinc concentration and clinical symptoms of the patient. In this way, when zinc acetate preparations are used for the treatment of hypozincemia, the dosage should be set appropriately according to the patient's condition. Setting is becoming possible. In order to use the present drug more effectively and safely, it is useful to support administration planning by the drug treatment management system of the present embodiment.

FIG. 2 is a diagram showing the configuration of the doctor terminal 10. As shown in FIG. In a preferred embodiment, the doctor terminal 10 has an input section 11 , an arithmetic processing section 12 , a communication section 13 , an output section 14 and a storage section 15 . The input unit 11 is composed of a keyboard and a mouse, and has a function of receiving input of patient data. The input unit 11 may have a configuration in which input is directly performed using a finger, a stylus pen, or the like on a touch panel formed on the terminal screen, in addition to a keyboard and mouse. Furthermore, depending on the data, it may be directly read from the measuring device via an electric communication line, or it may be input after being converted from image information obtained by photographing a document containing various information. Input patient data includes drug dosage data and serum zinc concentration data. In addition, patient data may include data on one or any combination of patient attribute data, underlying disease data, type of hypozincemia treatment drug, and data on other drugs being taken. good. Here, the patient attribute data includes age, sex, weight, and the like. In addition, the type of drug includes data on the dosage form of the drug, active ingredients, and the like.

The arithmetic processing unit 12 controls the doctor terminal 10, generates and displays a screen for inputting patient data, stores the input data in the storage unit 15, and receives the dose of medicine transmitted from the server 20. Generates and displays a screen showing the data of the recommended values of

The communication unit 13 has a function of communicating with the server 20 . Communication with the server 20 can be performed via an Internet line. The output unit 14 is composed of a monitor and a speaker, and displays various data and outputs audio.

FIG. 3 is a diagram showing the configuration of the server 20. As shown in FIG. In a preferred embodiment, the server 20 has an input section 21 , an arithmetic processing section 22 , an output section 23 , a communication section 24 and a storage section 25 . The input unit 21 has a function of receiving input of various data transmitted from the doctor terminal 10 via the communication unit 24 . The arithmetic processing unit 22 has a dosage calculation unit 26 that calculates a recommended drug dosage. and an analysis unit 27 that analyzes the relationship between Functions of the dose calculator 26 and the analyzer 27 will be described later.

The output unit 23 has a function of transmitting various output data to the doctor terminal 10 via the communication unit 24 . Also, the output unit 23 may include a monitor and a speaker, and may have functions such as displaying various data and outputting audio. The communication unit 24 has a function of communicating with the doctor terminal 10 .

The storage unit 25 stores various types of patient-related data transmitted from the doctor terminal 10 in association with patient identifiers. The patient data stored in the storage unit 25 includes drug dose data and serum zinc concentration data. In addition, patient data may include data on one or any combination of patient attribute data, underlying disease data, type of hypozincemia treatment drug, and data on other drugs being taken. good. Drug dose data and serum zinc concentration data are stored as time-series data from the past to the present.

FIG. 4 is a flow chart showing the processing performed by the dosage calculation unit 26. As shown in FIG. When the server 20 receives the drug dose to the patient and the serum zinc concentration data transmitted from the doctor terminal 10 through the communication unit 24, the received data is stored in the storage unit 25 (S10). The dose calculation unit 26 determines whether the received serum zinc concentration is within the normal range (S11). The normal range for serum zinc concentration as defined by the Society of Clinical Nutrition is 80-130 μg/dL. However, since the normal range used here is a numerical range used as an index for determining the necessity of dosage change, it does not necessarily correspond to the reference value established by the Japanese Society of Clinical Nutrition. For example, the lower limit of the normal range may be 60 μg/dL, 65 μg/dL, 75 μg/dL, or the like. Also, for example, the normal range may be 60 μg to 130 μg/dL.

If the serum zinc concentration is within the normal range, the dosage calculation unit 26 determines that the dosage should not be changed (that is, the previous dosage) as the recommended value (R1). If the serum zinc concentration is less than the lower limit of the normal range, the dose calculation unit 26 refers to the patient's time-series data and determines whether the administration period is longer than or equal to a predetermined period (S12). If the administration period is short, the effect of the drug may not yet appear. The length of the predetermined period is determined from the above point of view, and is, for example, two months. If the administration period is not equal to or longer than the predetermined period (NO in S12), the dosage calculation unit 26 determines that the dosage should not be changed as a recommended value (R2).

If the administration period is longer than or equal to the predetermined period (YES in S12), the dose calculator 26 determines whether the current dose is the maximum dose (S13). If the current dose is the maximum dose (YES in S13), the dose calculator 26 determines that the dose should not be changed as a recommended value (R3).

If the current dose is not the maximum dose (NO in S13), the dose calculator 26 determines whether or not the dose has been changed in the past (S14). If there is no record of change in the past (NO in S14), the dose calculator 26 determines a dose increased by a certain amount as a recommended value (R4). How much to increase can be determined based on the patient's age and weight. For example, 25 mg for adults or children weighing 30 kg or more, 15 mg for children weighing between 10 kg and 30 kg, and 5 mg for children weighing less than 10 kg.

If there is a record of dose change in the past (YES in S14), the dose calculator 26 calculates the patient's zinc absorption sensitivity from the past record (S15). In the present invention, the zinc absorption sensitivity is an index showing how much the ingested zinc changes the serum zinc concentration. A patient's sensitivity to zinc absorption can be determined by evaluating how much the drug administration improves the serum zinc concentration. Zinc absorption sensitivity may be determined, for example, based on past performance data regarding the amount of change in serum zinc concentration associated with changes in dosage. The zinc absorption sensitivity may be obtained by dividing the amount of change in serum zinc concentration when the dosage is changed by the amount of change in dosage. In the determination of zinc absorption sensitivity, it is desirable to use the average value of serum zinc concentrations within a certain period of time when the drug is administered at the same dosage. The dosage calculation unit 26 may use the analysis result by the analysis unit 27, which will be described later, when calculating the zinc absorption sensitivity. For example, a patient's zinc absorption sensitivity data having the same attribute may be used to correct the individual's zinc absorption sensitivity data.

The dose calculation unit 26 calculates a dose change value in consideration of the zinc absorption sensitivity data (S16), and determines a recommended dose value (R5). For patients with high zinc absorption sensitivity, the dose modification is small, and for patients with low zinc absorption sensitivity, the dosage modification is large. Specifically, with reference to the value of zinc absorption sensitivity, the dose change value is determined so as to achieve the target serum zinc concentration. For example, if the zinc absorption sensitivity was determined based on the change in serum zinc concentration divided by the change in drug dose, the current serum zinc concentration value and the target serum zinc concentration A dose modification value can be estimated based on the difference from the value.

Note that the relationship between the zinc absorption sensitivity and the change value may be stored in a table, and the dose calculation unit 26 may read the change value corresponding to the zinc absorption sensitivity from the table. The table can be created using past data. For example, the vertical column is the zinc absorption sensitivity, the horizontal column is the target increase in serum zinc concentration, and administration is performed in the frame corresponding to these. It can be an indication of the amount change value. FIG. 5 is a diagram showing an example of a table showing the relationship between zinc absorption sensitivity and change value. In this example, the zinc absorption sensitivity is defined as the rate of increase in serum zinc concentration when the daily dose is increased by 1 mg. According to the example shown in FIG. 5, when the target serum zinc concentration is 120 μg/dL, the dose is increased by 70 mg for a zinc absorption sensitivity of 0 to 0.5, and by 50 mg for a zinc absorption sensitivity of 0.5 to 1.0. An increase is associated. Here, an example is given in which the dose is defined by the increased amount of the drug, but it may be defined by the rate of increase with respect to the current dose. It goes without saying that the recommended dose cannot exceed the upper limit of the tolerable dose in any case.

When the patient's serum zinc concentration is higher than the upper limit of the normal range, the dose calculation unit 26 determines whether the dose is the minimum dose (S17). If the dose is not the minimum dose (NO in S17), the dose calculation unit 26 determines a dose reduced by a certain amount as a recommended value (R6). The amount of dose reduction can be determined based on the patient's age and weight, clinical symptoms, or how much the upper limit is exceeded. If the dose is the minimum dose (YES in S17), the dose calculation unit 26 determines that the drug administration should be stopped (that is, 0 mg/day) as the recommended value (R7).

When the dose calculation unit 26 determines the recommended dose (R1 to R7) as described above, the server 20 transmits data of the recommended drug dose to the doctor terminal 10 (S18). The doctor terminal 10 displays the recommended value data transmitted from the server 20 on the output unit 14 . Physicians refer to data on recommended levels to determine the amount of drug to administer to a patient. The doctor inputs the determined dose data to the doctor terminal 10 , and the doctor terminal 10 transmits the input dose data to the server 20 . The server 20 receives the dose data transmitted from the doctor terminal 10, associates the received dose data with the patient's identifier, and stores them in the storage unit 25 (S19). The data stored in the storage unit 25 is used when the dose calculation unit 26 calculates the drug dose next time.

Next, functions of the analysis unit 27 will be described. The server 20 is connected to a plurality of doctor terminals 10, and the drug dose and serum zinc concentration are transmitted from the doctor terminal 10 in order to calculate the recommended drug dose. The server 20 stores time-series data of drug dosages and serum zinc concentrations for many patients. In addition, as described above, the server 20 aggregates patient attribute data, underlying disease data, and drug type data. The analysis unit 27 has a function of analyzing the time-series data of drug dosage and serum zinc concentration stored in the storage unit 25 and analyzing the relationship between the two. At this time, by using patient attribute data, underlying disease data, and drug type data, the analysis unit 27 can detect differences due to attributes such as age and gender of the patient, differences due to the presence or absence of underlying diseases, and administered drugs. It is possible to perform detailed analysis by considering differences in the types of

The drug treatment management system 1 according to the first embodiment has been described above. The drug treatment management system 1 of the first embodiment outputs a recommended drug dose based on the time-series data of the drug dose and the serum zinc concentration. and can contribute to appropriate dosing regimens.

(Second embodiment)
Next, the configuration of the drug treatment management system of the second embodiment will be described. The basic configuration of the drug treatment management system of the second embodiment is the same as that of the first embodiment (see FIG. 1).

FIG. 6 is a diagram showing the configuration of the server 20 used in the drug treatment management system of the second embodiment. In the server 20 of the second embodiment, in addition to the configuration of the server 20 of the first embodiment, the arithmetic processing section 12 has a serum zinc concentration prediction section 28 . The serum zinc concentration prediction unit 28 has a function of obtaining a predicted change in serum zinc concentration based on patient's past data.

FIG. 7 is a flow chart showing the processing of the serum zinc concentration prediction unit 28. As shown in FIG. When the server 20 receives the patient's serum zinc concentration data transmitted from the doctor terminal 10 through the communication unit 24, the received data is stored in the storage unit 25 (S20). The serum zinc concentration prediction unit 28 calculates an approximate curve representing changes over time in the serum zinc concentration from past to present drug dosages to the patient and time-series data of the patient's serum zinc concentration (S21). Approximate curves can be obtained by various methods. For example, a theoretical formula representing pharmacokinetics may be fitted to data representing changes in serum zinc concentration. In addition, an arbitrary curve that minimizes the error with the data representing the transition of the serum zinc concentration (e.g., a formula having a typical shape representing the past transition, such as a trigonometric function or a higher-order expression) can be obtained by known curve fitting. It may be obtained by a method.

The serum zinc concentration prediction unit 28 uses the calculated data of the approximate curve to calculate the predicted transition of the patient's future serum zinc concentration (S22). At this time, if there is a record of changing the dosage in the past, that data can also be used. In a preferred embodiment, the serum zinc concentration prediction unit 28 also considers the value of zinc absorption sensitivity, and obtains prediction transitions for a plurality of drug dosage candidates. For example, predicted changes in serum zinc concentration are obtained for respective doses of 50 mg/day, 75 mg/day, and 100 mg/day. The server 20 transmits the obtained predicted transition data to the doctor terminal 10 (S18). In the doctor terminal 10 , the predicted transition data transmitted from the server 20 is displayed on the output unit 14 .

FIG. 8 is a diagram showing an example of predicted changes in serum zinc concentration displayed on the doctor terminal 10. As shown in FIG. In the example shown in FIG. 8, the serum zinc concentration is currently 60 μg/dL at a dose of 50 mg/day. As for the future, predicted changes in serum zinc concentration are shown for three patterns of 100 mg/day, 75 mg/day, and 50 mg/day. Here, an example of displaying three patterns of predicted transitions at the same time has been given, but an interface may be used in which the doctor inputs the dosage and displays the predicted transition corresponding to the input dosage.

Physicians can determine the amount of drug to be administered to the patient by referring to data on predicted changes in serum zinc concentration. The doctor inputs the determined dose data to the doctor terminal 10 , and the doctor terminal 10 transmits the input dose data to the server 20 . The server 20 receives the dose data transmitted from the doctor terminal 10, associates the received dose data with the patient's identifier, and stores them in the storage unit 25 (S24). The data stored in the storage unit 25 is used when the serum zinc concentration prediction unit 28 calculates the predicted transition next time.

Note that the drug treatment management system of the second embodiment may output a recommended value of the drug dosage, as in the drug treatment management system of the first embodiment. At this time, the future prediction of the serum zinc concentration when the drug is administered at the recommended level may also be displayed.

(Third Embodiment)
FIG. 9 is a diagram showing the configuration of the drug treatment management system 3 of the third embodiment. The basic configuration of the drug therapy management system 3 of the third embodiment is the same as the drug therapy management system 1 of the first embodiment, but the drug therapy management system 3 of the third embodiment includes: It has a wearable terminal 30 and a user terminal 31 owned by a patient. The wearable terminal 30 and the user terminal 31 are connected with the server 20 .

The wearable terminal 30 is worn around the patient's wrist, for example, and has a function of acquiring biometric data such as the patient's blood pressure, heart rate, and sleep time. The wearable terminal 30 transmits the acquired biometric data to the server 20 together with patient identification data. The server 20 stores the biometric data transmitted from the wearable terminal 30 in the storage unit 25 in association with the patient's identifier.

The user terminal 31 is, for example, a user's smart phone. The user terminal 31 accepts input of data such as the medication status and meal details, and transmits the entered medication status and meal data to the server 20 together with the patient's identification data. The server 20 associates the medication status and meal data transmitted from the user terminal 31 with the patient's identifier and accumulates them in the storage unit 25 .

By collecting the patient's biometric data in this way, comprehensive drug treatment management can be performed by taking into consideration not only the serum zinc concentration measured at the patient's hospital, but also the patient's daily health status. be able to. In addition, by collecting data on patient compliance, when analyzing the relationship between drug dosage and serum zinc concentration, it is possible to distinguish whether the drug is ineffective or whether the patient often forgets to take the drug. It should be noted that the wearable terminal 30 and the user terminal 31 do not have to be both set, and only one of them may be provided.

(Fourth embodiment)
FIG. 10 is a diagram showing the configuration of a drug treatment management system according to the fourth embodiment. A drug treatment management system according to the fourth embodiment is configured by a doctor terminal 40. FIG. The doctor terminal 40 has an input section 41 , an arithmetic processing section 42 , a communication section 43 , an output section 44 and a storage section 45 . The input unit 41 is composed of a keyboard and a mouse, and has a function of receiving input of patient data. The input unit 41 may have a configuration in which input is directly performed using a finger, a stylus pen, or the like on a touch panel formed on the terminal screen, in addition to a keyboard and mouse. The input patient data includes serum zinc concentration data. In addition, the patient data includes one or any combination of drug dosage, patient attribute data, underlying disease data, type of hypozincemia treatment drug, and data on other drugs taken. may include data for Here, the patient attribute data includes age, sex, weight, and the like. In addition, the type of drug includes data on the dosage form of the drug, active ingredients, and the like.

The arithmetic processing unit 42 controls the doctor terminal 40, generates and displays a screen for inputting patient data, stores the input data in the storage unit 45, and stores the input serum zinc concentration of the patient. Depending on the data, processing such as generating and displaying a screen related to the data is performed.

The communication unit 43 has a function of communicating with the zinc quantification device 50 . The method by which the zinc quantification device 50 quantifies zinc is not limited, but a method that can easily and quickly quantify the serum zinc concentration is desirable. By lowering the hurdles for measuring the serum zinc concentration, it is possible to increase the frequency of measurement and grasp the changes in the serum zinc concentration in detail. It is in the patient's interest to show a clear screen and provide an explanation. Communication with the zinc quantification device 50 may be performed via the Internet line, or may be performed using short-range wireless communication such as Bluetooth (registered trademark). In addition, the communication part 43 which communicates with the zinc quantification device 50 is arbitrary, and the communication part 43 which communicates with the zinc quantification device 50 may be omitted.

The output unit 44 is composed of a monitor and a speaker, and displays various data and outputs audio. The monitor is preferably a monitor that can be viewed by both the doctor and the patient. For example, the doctor's terminal may be a tablet terminal that can present the displayed screen to the patient. The output unit 44 also includes a printer for printing data such as the patient's serum zinc concentration.

In addition to storing patient data, the storage unit 45 stores serum zinc concentration classes and messages corresponding to the classes. FIG. 11 is a diagram showing an example of data stored in the storage unit 45. As shown in FIG. Classes are separated by concentration ranges of serum zinc concentrations. As shown in FIG. 11, in the present embodiment, class 1 (from 130 μg/dL), class 2 (80 to 130 μg/dL), class 3 (60 to 80 μg/dL), class 4 (to 60 μg/dL) has four classes of Note that the classes shown here are only examples. For example, class 2 may be further divided into two classes to make a total of five classes, or classes 3 and 4 may be combined to make a total of three classes. Also, the density area of each class may be changed.

Also, the messages stored in the storage unit 45 relate to the patient's condition corresponding to the serum zinc concentration, future measures, and the like. The message shown in FIG. 11 is an example and is not limited to this. In the example shown in FIG. 11, for class 1, it is ``Beware of a decrease in serum copper concentration. Consider measuring the serum copper concentration.'' . Regarding Class 3, Fig. 11 shows "Are you likely to get stomatitis? Is it difficult to understand the taste? Do you have dermatitis?" There are various symptoms, such as anemia, hair loss, and anorexia, so you may want to memorize these symptoms. Message data corresponding to the class is read out from the storage unit 45 , screen data is generated, and is displayed on the output unit 44 .

When the doctor terminal 40 of the present embodiment receives the patient's serum zinc concentration data from the input unit 41, the input data is stored in the storage unit 45, and a screen showing the input serum zinc concentration data (hereinafter referred to as , called “result display screen”). FIG. 12 is a diagram showing an example of a result display screen displayed on the monitor by the output unit 44. As shown in FIG. As shown in FIG. 12, the result display screen displays the input serum zinc concentration data (“140” μg/dL in this example) and the class to which this data belongs.

The display of classes displays all four classes and highlights the class to which the patient's serum zinc concentration data belongs. Although not shown in the drawing, each class is colored with a different color. With such a display mode, it is easy to understand where the class to which the patient's serum zinc concentration data belongs is located. In addition, on this screen, by expressing Class 1 as "High", Class 2 as "Normal range", Class 3 as "Slightly low", and Class 4 as "Low" in plain language, the patient can easily understand. can do.

Also, a message corresponding to the class is displayed on the result display screen. In the example shown in FIG. 12, as a message corresponding to class 1, the message "Beware of a decrease in serum copper concentration. Please consider measuring the serum copper concentration." By displaying the message corresponding to the class in this way, the doctor and the patient can share information about the patient's current condition and future treatment.

If the amount of information in the message corresponding to the class is large, a part of the message stored in the storage unit 45 may be selected and displayed. By limiting the amount of information displayed at one time, it is possible to maintain the readability of the message and the visibility of the result display screen. At this time, the message may be selected at random, or if the doctor terminal 40 stores patient-related information (sex, age, medical history, etc.), the message may be selected based on the patient's information. good.

The result display screen has a "back" button and a "history" button. When the "return" button is pressed, for example, the screen returns to the menu screen. When the "History" button is pressed, the screen transitions to a screen displaying the past history of serum zinc concentration data (hereinafter referred to as "history display screen").

FIG. 13 is a diagram showing an example of a history display screen. The history display screen displays the latest serum zinc concentration data (“140” μg/dL in this example). The history display screen displays a graph plotting past measurement result data of serum zinc concentration. In the graph, the shaded portion indicates the normal range. By displaying the history of the serum zinc concentration data in this way, it is possible to grasp the past trends.

The history display screen is provided with a "return" button and a "print" button. When the "return" button is pressed, the screen may return to the previous screen (FIG. 12) or the menu screen. When the "Print" button is pressed, the data of the serum zinc concentration measurement results are printed. As the measurement result data, the measurement date and serum zinc concentration data may be printed, or a graph as shown in FIG. 13 may be printed.

As shown in FIGS. 12 and 13, the doctor's terminal 40 of the fourth embodiment displays the class to which the serum zinc concentration data belongs so that the patient can grasp at a glance what the serum zinc concentration data means. It is easy to understand what you have. It is important that the doctor explains the patient's condition and treatment plan, and that the patient fully understands and agrees to receive treatment. In this embodiment, sharing this screen between the doctor and the patient makes it easier for the patient to understand the doctor's explanation. Further, since the doctor terminal 40 displays a message corresponding to the class as shown in FIG. 12, it is easy to understand future measures. FIG. 12 shows an example of a message corresponding to class 1. For example, as a message corresponding to class 3, "Are you likely to get stomatitis? Is the taste difficult to understand? Do you have dermatitis?" ' message, the patient can determine if they have a specific idea. Even if they are told that they have a latent zinc deficiency, they do not have any sense of it, but if they have any symptoms that come to mind, they will take medications and take positive measures to treat it.

The drug treatment management system according to the fourth embodiment has been described above. In the fourth embodiment, an example without the server 20 described in the first to third embodiments was given, but the drug treatment management system of the fourth embodiment also includes the server 20. good too.

Although the pharmaceutical treatment management system of the present invention has been described above with reference to the embodiments, the present invention is not limited to the above-described embodiments. In the drug treatment management system of the embodiment described above, when the received serum zinc concentration is higher than a predetermined threshold value, or when the serum zinc concentration continues to be higher than a predetermined threshold value several times, the serum copper concentration is measured. It is also possible to output a message prompting The predetermined threshold may be, for example, the upper limit of the normal range (eg, 130 μg/dL), or may be set higher or lower than that. When the serum zinc concentration is high, the absorption of copper is inhibited by zinc and side effects of copper deficiency may occur. This configuration can prevent the side effects of copper deficiency.

In the above-described first to third embodiments, an example of inputting serum zinc concentration data from the doctor terminal 10 has been described. good too. In this case, if the zinc quantification device simultaneously acquires additional information such as the patient's name, age, weight, underlying disease, and other medications taken from the bar code displayed in the inspection record, and transmits the information to the server, This saves doctors the trouble of entering data and prevents input errors.

1, 3 Drug therapy management system 10 Doctor terminal 11 Input unit 12 Arithmetic processing unit 13 Communication unit 14 Output unit 15 Storage unit 20 Server 21 Input unit 22 Arithmetic processing unit 23 Output unit 24 Communication unit 25 Storage unit 26 Dose calculation unit 27 Analysis unit 28 Serum zinc concentration prediction unit 30 Wearable terminal 31 User terminal 40 Doctor terminal 41 Input unit 42 Arithmetic processing unit 43 Communication unit 44 Output unit 45 Storage unit 50 Zinc quantification device

Claims (20)

A system for managing drug therapy for a patient with hypozincemia, comprising:
an input unit for accepting input of patient drug dosage data and patient serum zinc concentration data;
a storage unit that stores data on the drug dosage and the serum zinc concentration as time-series data;
a dose calculation unit that calculates a recommended dose of a drug based on the time-series data stored in the storage unit;
an output unit that outputs the recommended value;
A drug therapy management system comprising: 2. The drug treatment according to claim 1, wherein the dosage calculation unit calculates the zinc absorption sensitivity of the patient based on the patient's time-series data, and obtains a recommended drug dosage in consideration of the zinc absorption sensitivity. management system. 3. The drug treatment management system according to claim 1, wherein the dose calculation unit obtains a recommended drug dose in consideration of a drug administration period. a serum zinc concentration prediction unit that calculates predicted changes in future serum zinc concentration according to drug dosage based on the time-series data stored in the storage unit;
4. The drug treatment management system according to any one of claims 1 to 3, wherein said output unit outputs data of predicted transition of said serum zinc concentration. 5. The drug treatment management system according to any one of claims 1 to 4, wherein said output unit outputs a message prompting measurement of serum copper concentration when the input serum zinc concentration is higher than a predetermined threshold. 5. The output unit according to claim 4, wherein the output unit outputs a message prompting measurement of the serum copper concentration when the predicted value of the serum zinc concentration indicated by the calculated predicted transition of the serum zinc concentration is higher than a predetermined threshold. Drug treatment management system. a plurality of terminals having the input unit; and a server connected to the plurality of terminals via a network and collecting and storing the drug dosage data and the serum zinc concentration data input from the terminals. prepared,
7. The server according to any one of claims 1 to 6, wherein the server comprises an analysis unit that analyzes the relationship between the drug dose and the serum zinc concentration transition based on the time-series data of the drug dose and the serum zinc concentration of a large number of patients. 1. The drug therapy management system according to 1. The input unit receives input of patient attribute data or underlying disease data,
The server stores the drug dosage data for the patient and the serum zinc concentration data for the patient in association with patient attribute data or underlying disease data,
8. The drug treatment management system according to claim 7, wherein the analysis unit analyzes patient attribute data or underlying disease data, and the relationship between drug dosage and changes in serum zinc concentration. The input unit receives input of data on the type of drug administered to the patient,
The server stores the drug dosage data for the patient and the serum zinc concentration data for the patient in association with data on the type of drug administered to the patient;
9. The drug treatment management system according to claim 7, wherein the analysis unit analyzes the relationship between drug type data, drug dosage, and changes in serum zinc concentration. The input unit receives input of data of other drugs that the patient is taking,
The server stores the drug dosage data for the patient and the serum zinc concentration data for the patient in association with data for other drugs the patient is taking;
10. The drug treatment management system according to any one of claims 7 to 9, wherein the analysis unit analyzes data of other drugs, drug doses, and changes in serum zinc concentration. A wearable terminal that measures the patient's biometric data and transmits the measured biometric data to the server together with the patient's identifier,
11. The pharmaceutical treatment management system according to any one of claims 7 to 10, wherein the server stores the biometric data transmitted from the wearable terminal together with the patient's identifier. A system for managing drug therapy for a patient, comprising:
an input unit for receiving input of data on drugs administered to a patient and data on serum elemental concentrations of the patient;
a storage unit for storing the drug-related data and the serum elemental concentration data as time-series data;
a dose calculation unit that calculates a recommended dose of a drug based on the time-series data stored in the storage unit;
an output unit that outputs the recommended value;
A drug therapy management system comprising: A method of managing drug therapy for a patient with hypozincemia by a drug therapy management system, comprising:
the drug therapy management system accepting input of patient drug dosage data and patient serum zinc concentration data;
a step in which the drug treatment management system stores data on the drug dosage and the serum zinc concentration as time-series data in a storage unit;
determining a recommended drug dosage based on the time-series data stored in the storage unit by the drug treatment management system;
the drug therapy management system outputting the recommended value;
A drug therapy management method comprising: A program for managing drug therapy for hypozincemia patients by a drug therapy management system, comprising:
receiving patient drug dosage data and patient serum zinc concentration data;
obtaining a drug dosage recommendation based on the time series data of the drug dosage and the serum zinc concentration;
outputting the recommended value;
program to run. A program for managing drug therapy for hypozincemia patients by a drug therapy management system, comprising:
receiving patient drug dosage data and patient serum zinc concentration data;
a step of obtaining data on predicted changes in the future serum zinc concentration according to the drug dosage, based on the time-series data of the drug dosage and the serum zinc concentration;
a step of outputting data on the predicted transition of the serum zinc concentration;
program to run. 16. The program according to claim 15, wherein, in the step of outputting the predicted transition data of the serum zinc concentration, a plurality of drug dosage candidates and the predicted transition of the serum zinc concentration corresponding to each candidate are displayed. A system for managing drug therapy for a patient with hypozincemia, comprising:
an input unit for receiving input of patient serum zinc concentration data;
a determination unit that determines to which class the input patient's serum zinc concentration belongs to among a plurality of concentration region classes;
an output unit that displays the class and displays information corresponding to the class;
A drug therapy management system comprising: 18. The drug treatment management system according to claim 17, wherein the information corresponding to the class of the serum zinc concentration range equal to or higher than the specific value includes a message prompting measurement of the serum copper concentration. A method of managing drug therapy for a patient with hypozincemia by a drug therapy management system, comprising:
receiving patient serum zinc concentration data input by the drug therapy management system;
determining to which class the input patient's serum zinc concentration belongs to among a plurality of concentration region classes;
the drug therapy management system displaying the class and displaying information corresponding to the class;
A drug therapy management method comprising: A program for managing drug therapy for a patient with hypozincemia, comprising:
receiving input of patient serum zinc concentration data;
determining to which class the input patient's serum zinc concentration belongs to among a plurality of concentration region classes;
displaying the class and displaying information corresponding to the class;
program to run.

Images